← Back to Search

Virus Therapy

Mitoquinone/mitoquinol mesylate for COVID-19

Phase 1 & 2

Waitlist Available

Led By Theodoros Kelesidis, MD PHD

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 14 days

Awards & highlights

Study Summary

This trial will test if the diet supplement Mito-MES can prevent severe viral infections like COVID-19 after exposure to someone with a possible respiratory viral infection.

Eligible Conditions

COVID-19
Viral Respiratory Infection
Coronavirus
Antiviral Treatment

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 14 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~14 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with viral illness

Severity score of symptoms of viral illness

Secondary outcome measures

Incidence of Treatment-Emergent Adverse Events as assessed by the proportion of participants exhibiting adverse events of any grade

Number of participants with any symptoms of viral illness

Number of participants with fever

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: MitoQExperimental Treatment1 Intervention

Treatment group

Group II: Control groupActive Control1 Intervention

Control group

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Mitoquinone/mitoquinol mesylate

2022

Completed Phase 2

~80

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,047 Previous Clinical Trials

1,053,719 Total Patients Enrolled

5 Trials studying COVID-19

7,542 Patients Enrolled for COVID-19

University of California, Los AngelesLead Sponsor

1,528 Previous Clinical Trials

10,276,771 Total Patients Enrolled

21 Trials studying COVID-19

873,524 Patients Enrolled for COVID-19

Theodoros Kelesidis, MD PHDPrincipal InvestigatorUniversity of Texas Southwestern Medical Center

1 Previous Clinical Trials

20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are people currently being accepted into this trial?

"Yes, this research is ongoing and actively recruiting patients according to the website clinicaltrials.gov. The listing for this study was originally posted on April 28th, 2022 and was last updated on August 3rd of the same year."

Answered by AI

Could people who are under the age of 65 still qualify for this test program?

"This trial's parameters state that only individuals aged 18 to 65 can apply. There are 190 other trials for minors and 1,048 studies available for senior citizens."

Answered by AI

How many test subjects are presently signed up for this experiment?

"That is correct, the trial is still open and actively recruiting patients. According to information on clinicaltrials.gov, which was last updated on 8/3/2022, the study is looking for 100 participants at 1 site."

Answered by AI

Who meets the guidelines to be a part of this experiment?

"This study is looking for 100 participants who are currently infected with covid-19 and meet the following additional criteria: they must be between 18 and 65 years old, asymptomatic on entry to the trial, have been exposed to someone with viral illness within 3 days prior to entering the trial, ineligible for other FDA approved treatments, without significant coronary artery/vascular disease, lung, stroke, kidney, liver or heart disease based on history, and have adequate renal function."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness

Theodoros Kelesidis 2022. "An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05381454.